USA flag logo/image

An Official Website of the United States Government

THE OBJECTIVE OF THIS STUDY IS TO SYNTHESIZE, CHARACTERIZE, AND EVALUATE…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
3011 		Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3011 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
AMT, INC.
508 HEARTWOOD RD CHERRY HILL, NJ 08003 CHERRY HILL, NJ 08003
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THE OBJECTIVE OF THIS STUDY IS TO SYNTHESIZE, CHARACTERIZE, AND EVALUATE BIOLOGICAL PROPERTIES OF POLYMERIC PLATINUM COMPLEXES IN AN EFFORT TO ENHANCE SOLUBILITY AND STABILITY WHILE REDUCING TOXICITY AND OBTAINING GREATER SUSTAINED ACTIVITY THAN THAT
Agency: HHS
Contract: N/A
Award Amount: $49,839.00
 

Abstract:

THE OBJECTIVE OF THIS STUDY IS TO SYNTHESIZE, CHARACTERIZE, AND EVALUATE BIOLOGICAL PROPERTIES OF POLYMERIC PLATINUM COMPLEXES IN AN EFFORT TO ENHANCE SOLUBILITY AND STABILITY WHILE REDUCING TOXICITY AND OBTAINING GREATER SUSTAINED ACTIVITY THAN THAT FOUND WITH ACTIVE, STRUCTURALLY RELATED, MONOMERIC COMPLEXES. THE PHASE I RESEARCH PLAN IS BASED ON THE PROMISING PRELIMINARY IN VIVO RESULTS OBTAINED FOR A DACH-PT COMPLEX WITH THE POLYANION OF POLY(METHACRYLIC ACID) (PMA), A BIOCOMPATIBLE, HYDROPHILIC POLYMER. THIS COMPLEX HAS EXHIBITED BETTER IN VIVO ANTITUMOR ACTIVITY AND THERAPEUTIC INDEX THAN THE CORRESPONDING MONOMERIC ANALOG IN TUMORED MICE. IN PHASE I RESEARCH, THE EFFECT OF MOLECULAR WEIGHT AND MICROSTRUCTURE OF PMA ON COMPLEX STABILITY AND ANTITUMOR ACTIVITY WILL BE INVESTIGATED. NEW POLYMERIC ANALOGS OF GENERAL FORMULA PT(DACH)POLYCARBOXYLATE WILL ALSO BE SYNTHESIZED AND EVALUATED IN VIVO FOR THEIR ANTITUMOR ACTIVITY AGAINST L1210 LEUKEMIA IN MICE. THE SUCCESSFUL DEVELOPMENT OF POLYMERIC PLATINUM COMPLEXES EXHIBITING ANTINEOPLASTIC ACTIVITY WILL YIELD A TOTALLY NEW CLASS OF ANTICANCER AGENTS WHOSE UNIQUE PHYSICAL AND CHEMICAL CHARACTERISTICS WOULD BE EXPECTED TO EXHIBIT SIMILARLY UNIQUE CLINICAL CHARACTERISTICS, PROSPECTIVELY ENHANCING THE THERAPEUTIC EFFECT AND ACCEPTANCE OF CHEMOTHERAPY BY CANCER PATIENTS.

Principal Investigator:

Devinder gill
PRINCIPAL INVESTIGATOR
3016571700

Business Contact:

Small Business Information at Submission:

Andrulis Research Corp
7315 Wisconsin Avenue, Suite 6 50n Bethesda, MD 20814

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No